American Century Companies Inc. Acquires 17,460 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

American Century Companies Inc. lifted its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 12.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 159,782 shares of the company’s stock after buying an additional 17,460 shares during the quarter. American Century Companies Inc. owned about 0.84% of USANA Health Sciences worth $7,229,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in USNA. Quest Partners LLC bought a new stake in shares of USANA Health Sciences during the fourth quarter valued at approximately $66,000. CWM LLC increased its stake in shares of USANA Health Sciences by 21.8% in the 1st quarter. CWM LLC now owns 1,543 shares of the company’s stock valued at $75,000 after buying an additional 276 shares during the period. BOKF NA raised its position in shares of USANA Health Sciences by 274.5% during the first quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after acquiring an additional 2,031 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of USANA Health Sciences during the fourth quarter valued at $266,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock valued at $284,000 after acquiring an additional 494 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on USNA shares. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th. DA Davidson cut their price objective on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, July 25th.

Insider Activity

In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Insiders have sold 7,940 shares of company stock worth $311,670 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

USANA Health Sciences Trading Down 1.3 %

USANA Health Sciences stock opened at $38.08 on Tuesday. USANA Health Sciences, Inc. has a 1 year low of $36.05 and a 1 year high of $60.03. The firm has a market capitalization of $725.46 million, a P/E ratio of 11.86, a PEG ratio of 1.28 and a beta of 0.90. The business has a 50-day moving average of $40.76 and a 200-day moving average of $44.34.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). The firm had revenue of $212.87 million during the quarter, compared to the consensus estimate of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same quarter in the prior year, the company earned $0.89 EPS. Research analysts anticipate that USANA Health Sciences, Inc. will post 2.5 EPS for the current fiscal year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.